BioPharma Dive November 15, 2024
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke with BioPharma Dive about how the company came together.
Trace Neuroscience, a freshly launched startup, is developing a type of genetic medicine it believes could help most, if not all, people with ALS.
It’s a bold idea, considering nearly every attempt to combat the nerve-destroying disease has ended in failure. Researchers still aren’t sure what causes 90% of cases. And in the U.S., the short list of drugs approved to treat ALS, or amyotrophic lateral sclerosis, got shorter still this year, as a once-promising medication hit a major setback that ultimately got it pulled from the market.
Yet Trace was still...
Today's Sponsors
Today's Sponsor